Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Hendrik J. Nel"'
Autor:
Amee Sonigra, Hendrik J. Nel, Pascale Wehr, Nishta Ramnoruth, Swati Patel, Karin A. van Schie, Maxwell W. Bladen, Ahmed M. Mehdi, Joanne Tesiram, Meghna Talekar, Jamie Rossjohn, Hugh H. Reid, Frederik E. Stuurman, Helen Roberts, Phillip Vecchio, Ian Gourley, Mark Rigby, Stephane Becart, Rene E.M. Toes, Hans Ulrich Scherer, Kim-Anh Lê Cao, Kim Campbell, Ranjeny Thomas
Publikováno v:
JCI Insight, Vol 7, Iss 20 (2022)
BACKGROUND Antigen-specific regulation of autoimmune disease is a major goal. In seropositive rheumatoid arthritis (RA), T cell help to autoreactive B cells matures the citrullinated (Cit) antigen-specific immune response, generating RA-specific V do
Externí odkaz:
https://doaj.org/article/25d3db325866461e8778f8d46b427806
Autor:
Carla J. Greenbaum, Elisavet Serti, Katharina Lambert, Lia J. Weiner, Sai Kanaparthi, Sandra Lord, Stephen E. Gitelman, Darrell M. Wilson, Jason L. Gaglia, Kurt J. Griffin, William E. Russell, Philip Raskin, Antoinette Moran, Steven M. Willi, Eva Tsalikian, Linda A. DiMeglio, Kevan C. Herold, Wayne V. Moore, Robin Goland, Mark Harris, Maria E. Craig, Desmond A. Schatz, David A. Baidal, Henry Rodriguez, Kristina M. Utzschneider, Hendrik J. Nel, Carol L. Soppe, Karen D. Boyle, Karen Cerosaletti, Lynette Keyes-Elstein, S. Alice Long, Ranjeny Thomas, James G. McNamara, Jane H. Buckner, Srinath Sanda, for the ITN058AI EXTEND Study Team
Publikováno v:
JCI Insight, Vol 6, Iss 21 (2021)
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in
Externí odkaz:
https://doaj.org/article/083a57294536479793c92cf07ad43e13
Autor:
Yassmin Musthaffa, Hendrik J. Nel, Nishta Ramnoruth, Swati Patel, Emma E. Hamilton-Williams, Mark Harris, Ranjeny Thomas
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The development of tolerizing therapies aiming to inactivate autoreactive effector T-cells is a promising therapeutic approach to control undesired autoimmune responses in human diseases such as Type 1 Diabetes (T1D). A critical issue is a lack of se
Externí odkaz:
https://doaj.org/article/36d3c793c3b642d8b4caf8e0e08c101d
Autor:
Paulina A. García-González, Jaxaira Maggi, Katina Schinnerling, Alejandro Sepúlveda-Gutiérrez, Lilian Soto, Oscar Neira, Ahmed M. Mehdi, Hendrik J. Nel, Bárbara Pesce, Octavio Aravena, María Carmen Molina, Diego Catalán, Ranjeny Thomas, Ricardo A. Verdugo, Juan Carlos Aguillón
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
The potential of tolerogenic dendritic cells (tolDCs) to shape immune responses and restore tolerance has turn them into a promising therapeutic tool for cellular therapies directed toward immune regulation in autoimmunity. Although the cellular mech
Externí odkaz:
https://doaj.org/article/7fb74e75ba6b42cab167b149b15c222c
Autor:
Diahann T. S. L. Jansen, Nishta Ramnoruth, Khai L. Loh, Jamie Rossjohn, Hugh H. Reid, Hendrik J. Nel, Ranjeny Thomas
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
With the advent of novel strategies to induce tolerance in autoimmune and autoimmune-like conditions, clinical trials of antigen-specific tolerizing immunotherapy have become a reality. Besides safety, it will be essential to gather mechanistic data
Externí odkaz:
https://doaj.org/article/24fb871f208c46acb03afd4bcca98903
Autor:
Paulina A. García-González, Katina Schinnerling, Alejandro Sepúlveda-Gutiérrez, Jaxaira Maggi, Ahmed M. Mehdi, Hendrik J. Nel, Bárbara Pesce, Milton L. Larrondo, Octavio Aravena, María C. Molina, Diego Catalán, Ranjeny Thomas, Ricardo A. Verdugo, Juan C. Aguillón
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
There is growing interest in the use of tolerogenic dendritic cells (tolDCs) as a potential target for immunotherapy. However, the molecular bases that drive the differentiation of monocyte-derived DCs (moDCs) toward a tolerogenic state are still poo
Externí odkaz:
https://doaj.org/article/f7d45918c8324f22a733ba8475b062f6
Autor:
Zaied Ahmed, Bhuyan, M Arifur, Rahman, Muralidhara Rao, Maradana, Ahmed M, Mehdi, Anne-Sophie, Bergot, Davide, Simone, Marya, El-Kurdi, Jose, Garrido-Mesa, Cheng Bang Benjamin, Cai, Amy J, Cameron, Aimee L, Hanson, Hendrik J, Nel, Tony, Kenna, Paul, Leo, Linda, Rehaume, Matthew A, Brown, Francesco, Ciccia, Ranjeny, Thomas
Publikováno v:
Clinical immunology (Orlando, Fla.).
Disturbances in immune regulation, intestinal dysbiosis and inflammation characterize ankylosing spondylitis (AS), which is associated with RUNX3 loss-of-function variants. ZAP70
Autor:
Linda Rehaume, Páraic Ó Cuív, Kate L Bowerman, Timothy J. Wells, Helen Benham, Rabia Moentadj, Amalina Baharom, Philip Hugenholtz, Mark Morrison, Juliette E. Stephens, Ranjeny Thomas, Kim-Anh Lê Cao, Vanessa Anne Lakis, Muralidhara Rao Maradana, Yiwen Wang, Hendrik J. Nel
Publikováno v:
Annals of the Rheumatic Diseases. 80:573-581
ObjectivesAnalysis of oral dysbiosis in individuals sharing genetic and environmental risk factors with rheumatoid arthritis (RA) patients may illuminate how microbiota contribute to disease susceptibility. We studied the oral microbiota in a prospec
Autor:
Linda A. Bradbury, Kim-Anh Lê Cao, Hendrik J. Nel, Tony J. Kenna, Aimee L. Hanson, Julie Phipps, Matthew A. Brown, Ranjeny Thomas
Publikováno v:
Arthritis & Rheumatology. 72:1289-1302
Ankylosing spondylitis (AS) is a common spondyloarthropathy primarily affecting the axial skeleton and strongly associated with HLA-B*27 carriage. Genetic evidence implicates both autoinflammatory processes and autoimmunity against a HLA-B*27-restric
Autor:
Antoinette Moran, S. Alice Long, Philip Raskin, James McNamara, William E. Russell, Carol L. Soppe, Sai Kanaparthi, Elisavet Serti, Hendrik J. Nel, Kevan C. Herold, Sandra Lord, Lia J Weiner, Steven M. Willi, Lynette Keyes-Elstein, Kurt J Griffin, Robin Goland, Ranjeny Thomas, Stephen E. Gitelman, Mark Harris, Henry Rodriguez, Karen Cerosaletti, Linda A. DiMeglio, Darrell M. Wilson, Itn Ai Extend Study Team, Wayne V. Moore, Srinath Sanda, Carla J. Greenbaum, Maria E. Craig, David A. Baidal, Kristina M. Utzschneider, Jason L. Gaglia, Katharina Lambert, Eva Tsalikian, Karen D. Boyle, Desmond A. Schatz, Jane H. Buckner
Publikováno v:
JCI Insight
JCI insight, vol 6, iss 21
JCI insight, vol 6, iss 21
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in